HHS acknowledged in a statement on Operation Trailblazer that "a growing share of early-stage clinical research has moved ...

For GSK, ASCO 2026 was about long-term follow-up data, with new data from ongoing trials of Jemperli and Blenrep. Eric ...

In a landmark decision for people with early type 1 diabetes (T1D) in the UK, Sanofi's first-of-its-kind therapy Tzield, ...

One of the antibody-drug conjugates at the heart of Pfizer's $43 billion acquisition of Seagen three years ago has failed a keenly anticipated phase 3 trial in lung cancer. The results of the ...

MSD's tulisokibart has become the first anti-TL1A antibody to help patients with a type of inflammatory bowel disease (IBD) achieve clinical remission in a phase 3 trial. The drug – which MSD acquired ...

CARSgen Therapeutics has claimed approval in China, its home market, for satricabtagene autoleucel (satri-cel), said to be ...

With the third trial in the programme, Boehringer has set its sights on positioning Hernexeos as adjuvant monotherapy – ...

Genpact and analyst firm HFS Research have published a new global study, ‘The $18 Trillion Opportunity: How Four Enterprise ...

Details are starting to emerge of last week's cyberattack on Novo Nordisk, which now appears to have been a $25 million ...

In the first piece of news from the BIO conference that gets underway in San Diego today, Insilico Medicine has teamed up ...

The first generic alternative to Roche's oral drug for influenza, Xofluza, has been approved by the FDA and should be ...

The FDA refused to accept uniQure's filing for AMT-130 last November, and earlier this year the Dutch biotech said it had ...